Regulatory Filings • Jun 28, 2016
Regulatory Filings
Open in ViewerOpens in native device viewer
_________ false
C003������� �� ��� ��"�2PublicBIOLINE RX LTD9253Corporation no: 513398750Stock Exchange/Market: NASDAQ CM2271381HaMa'ayan 2 , Modi'in 7177871 , , IsraelTel: 08-6429100 , Fax: 08-6429101E.mail address: [email protected] via MAGNA: 28/06/2016 Time of broadcast: 13:48 13:38:54
| Company site: | www.biolinerx.com |
Reference: 2016-02-068407
| Israel Securities Authority | Tel Aviv Stock Exchange | |||||
| www.isa.gov.il | www.tase.co.il |
Other Report or AnnouncementRegulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000 The corporation is a foreign private issuer as defined by U.S. Securities Laws.
| Attached hereto is a report on | BioLineRx Announces Regulatory Submissions for Phase 2a Trial of BL-8040 in Combination with KEYTRUDA� (pembrolizumab) for Treatment of Pancreatic Cancer |
6-K_BL8040_280616_isa.pdf
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): |
| 2016-02-008722 |
| Previous names of reporting entity: |
| Date of revision of form structure: 08/06/2016 |
| - - - |
| Name of the Signatory: : Kotler Norman Harold , Position of Signatory in the reporting corporation: General Counsel & Company Secretary , Name of Employer Company: . |
| Hartum 19 Jerusalem 9777518 Telephone: 02-5489100 , Facsimile: 02-5489101 , E-mail: [email protected] 1 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.